Skip to main
PRCT
PRCT logo

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics Corp has demonstrated a consistent quarter-over-quarter growth in utilization of its systems, with an average increase of approximately 6.1% over the last six quarters. The company has strategically aimed to manage its operating expenses, intending to grow them at half the rate of top-line growth, which has been positively received by the market and suggests a clearer path to profitability. Looking ahead, implied handpiece utilization growth is projected to accelerate in FY26, hinting at potential revenue expansion as the company capitalizes on its innovative robotic systems in the urology sector.

Bears say

PROCEPT BioRobotics Corp has experienced a substantial decline in its stock value, with shares down approximately 54% year-to-date, despite the company’s ability to exceed its own financial guidance. The company's outlook is further complicated by potential downside risks, including a forecasted decline in capital equipment demand, reduced handpiece usage from existing customers, and intensified competitive pressures within the surgical robotics market. Additionally, impending changes to reimbursement policies for Aquablation therapy could adversely impact the company's revenue streams, further exacerbating concerns about its financial performance.

PRCT has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 7 analysts, PRCT has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.